Intchains Group
ICG
Argo Blockchain
ARBK
MARA Holdings
MARA
FRMO CORP
FRMO
Canaan
CAN
US Stock MarketDetailed Quotes
LVTX LAVA Therapeutics
- 1.410
- +0.090+6.82%
Close Mar 6 16:00 ET
- 1.420
- +0.010+0.71%
Post 20:01 ET
37.08MMarket Cap-1.40P/E (TTM)
1.420High1.330Low199.02KVolume1.350Open1.320Pre Close276.19KTurnover1.96%Turnover RatioLossP/E (Static)26.30MShares4.21052wk High1.12P/B14.29MFloat Cap0.85052wk Low--Dividend TTM10.14MShs Float17.200Historical High--Div YieldTTM6.82%Amplitude0.850Historical Low1.387Avg Price1Lot Size
Trending Stocks
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
LAVA Therapeutics Stock Forum
LAVA Therapeutics NV - to Explore Diverse Strategic Options Including Sale or Merger! LAVA Therapeutics NV - Initiates Strategic Review and Implements Workforce Reduction
LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers
Friday, 10th January at 8:23 am
LAVA-1266 is a potent and selective bispecific anti-CD123 Gammabody®
First-in-human study enrolling adult patients with CD123-expressing AML or MDS
Initial Phase 1 data read-out expected by year-end 2025
UTRECHT, The Netherlands and PHILADELPHIA, Jan. 10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, "LAVA, " "the Company")), a clinical-...
No comment yet